Skip to search formSkip to main contentSkip to account menu

Radotinib

Known as: 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

IY5511
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.
2019
2019
What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
infection caused by nilotinib. However, nilotinib may also be a risk factor for TB by inhibiting T cell-mediated immune responses… 
2017
2017
Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up
Background In RERISE phase 3 study, radotinib demonstrated significantly higher and faster rates of major molecular response (MMR… 
2017
2017
Radotinib for CML Yields Better Responses Than Imatinib
Among patients with newly diagnosed, chronic-phase chronic myeloid leukemia, a lower-dose regimen of radotinib demonstrated… 
2016
2016
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses
Abstract A fixed dose regimen for tyrosine kinase inhibitors (TKIs) is postulated to be responsible for variable safety outcomes… 
2016
2016
Teratogenic Effect of Radotinib: Case Report.
BACKGROUND Simultaneous presentation of pregnancy and chronic myeloid leukemia (CML) is rare. Tyrosine kinase inhibitors (TKIs… 
2016
2016
Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)
viability, with an IC50 of 20μM for sensitive cells and 25μM for Imatinib resistant cell lines. The cell death was induced by… 
2015
2015
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q 
2015
2015
Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”
Radotinib is effective and well tolerated in chronic phasechronic myeloid leukemia patients with resistance and/or intolerance to… 
2014
2014
Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib
Background: Second-generation BCR-ABL tyrosine kinase inhibitors (2nd generation TKIs) including nilotinib (NIL) and radotinib… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)